Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
1(6%)
Results Posted
30%(3 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_1
2
13%
Ph phase_4
3
19%
Ph not_applicable
5
31%
Ph phase_3
2
13%
Ph phase_2
3
19%

Phase Distribution

2

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
2(13.3%)
Phase 2Efficacy & side effects
3(20.0%)
Phase 3Large-scale testing
2(13.3%)
Phase 4Post-market surveillance
3(20.0%)
N/ANon-phased studies
5(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.9%

10 of 13 finished

Non-Completion Rate

23.1%

3 ended early

Currently Active

1

trials recruiting

Total Trials

16

all time

Status Distribution
Active(1)
Completed(10)
Terminated(3)
Other(2)

Detailed Status

Completed10
Withdrawn2
unknown2
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
1
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (13.3%)
Phase 23 (20.0%)
Phase 32 (13.3%)
Phase 43 (20.0%)
N/A5 (33.3%)

Trials by Status

withdrawn213%
recruiting16%
completed1063%
terminated16%
unknown213%

Recent Activity

1 active trials
Showing 5 of 16
recruitingphase_4

Calcium-Phosphorus Regulation Therapy on Heart Valve Disease

NCT06660524
completedphase_2

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)

NCT02124759
completednot_applicable

GLP-1-mediated Gluco-metabolic Effects of Bile Acid Sequestration

NCT03739268
completedphase_1

Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers

NCT00875017
completedphase_2

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)

NCT02127125
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT06660524Phase 4

Calcium-Phosphorus Regulation Therapy on Heart Valve Disease

Recruiting
NCT02124759Phase 2

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)

Completed
NCT03739268Not Applicable

GLP-1-mediated Gluco-metabolic Effects of Bile Acid Sequestration

Completed
NCT00875017Phase 1

Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers

Completed
NCT02127125Phase 2

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)

Completed
NCT03305471Phase 1

DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

Completed
NCT00364000Not Applicable

Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate

Withdrawn
NCT02445508Not Applicable

Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion

Completed
NCT01057186

Hypophosphatemic Rickets in Norway

Unknown
NCT01011699Phase 3

Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients

Terminated
NCT01968759Phase 2

Sevelamer in Proteinuric CKD

Completed
NCT02199444Phase 3

Effect of Sevelamer on P-cresol Levels in CKD

Unknown
NCT00837655Not Applicable

Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD)

Withdrawn
NCT01135615Phase 4

Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)

Completed
NCT00211939Phase 4

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

Completed
NCT00018135Not Applicable

Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16